Intralesional Recombinant Alpha-2a Interferon for the Treatment of Patients With Verruca
Annals of Dermatology
;
: 155-159, 2000.
Article
in English
| WPRIM
| ID: wpr-22067
ABSTRACT
BACKGROUND:
Interferon alpha-2a has already been shown to be effective in clinical use of virus-originated diseases such as hairy cell leukemia, condyloma acuminatum, and AIDS-related Kaposi's sarcoma. The use of recombinant alpha-interferon may allow common warts to be treated relatively atraumatically and with less incidence of recurrence.OBJECTIVE:
We tried to determine the safety and effectiveness of intralesional injections of recombinant alpha-2a interferon in the treatment of patients with common warts.METHODS:
A single wart on each patient was weekly injected with 0.75 to 1.5×10(5) IU/25mm2 of interferon for 8 weeks, and the response to treatment was followed up-to 6 months.RESULTS:
Clearing of the treated wart at the end of treatment occurred in 5(71%) out of 7 patients and the rest showed no improvement. With evaluation for relapses up-to 6 months after treatment, warts relapsed in 2(40%) out of 5 patients. Therefore, 3(43%) out of 7 patients were completely free of warts 6 months after treatment.CONCLUSION:
Intralesional recombinant interferon alpha-2a has a limited therapeutic effect, but may be considered as a therapeutic modality of recalcitrant verruca or when it can be anticipated that destructive techniques or blistering agents will not be tolerated.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Recurrence
/
Sarcoma, Kaposi
/
Warts
/
Leukemia, Hairy Cell
/
Injections, Intralesional
/
Incidence
/
Blister
/
Interferons
/
Interferon-alpha
Type of study:
Incidence study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Annals of Dermatology
Year:
2000
Type:
Article
Similar
MEDLINE
...
LILACS
LIS